Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients

Social Science and Medicine

Volumn 68, Issue 6, 2009, Pages 1044-1049

  Lima, Viviane ^a   Fernandes, Kimberly ^a   Rachlis, Beth ^a   Druyts, Eric ^a   Montaner, Julio ^a   Hogg, Robert ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

Adherence; Canada; HAART; HIV AIDS; Migration; Treatment outcomes

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; MIGRATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; RESIDENTIAL MOBILITY; SEX FACTORS; TIME FACTORS;

BRITISH COLUMBIA; CANADA; NORTH AMERICA;

EID: 62149123695     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2008.12.043     Document Type: Article

References (36)

1. Acorn S. Mental and physical health of homeless persons who use emergency shelters in Vancouver. Hospital & Community Psychiatry 44 9 (1993) 854-857
2. Agee B.S., Funkhouser E., Roseman J.M., Fawal H., Holmberg S.D., and Vermund S.H. Migration patterns following HIV diagnosis among adults residing in the nonurban Deep South. AIDS Care 18 Suppl. 1 (2006) S51-S58
3. Bangsberg D.R., Moss A.R., and Deeks S.G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. Journal of Antimicrobial Chemotherapy 53 5 (2004) 696-699
4. British Columbia Centre for Excellence in HIV/AIDS. Therapeutic guidelines (2006). Accessed 10.11.06)
5. City of Vancouver's Central Area Planning Department. 2004 Downtown eastside community monitoring report. Chinatown, Gastown, Oppenheimer, Strathcona, Victory Square. 9th ed. (2004). Accessed 30.11.07
6. Corneil T.A., Kuyper L.M., Shoveller J., Hogg R.S., Li K., Spittal P.M., et al. Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place 12 1 (2006) 79-85
7. Delgado J., Heath K.V., Yip B., Marion S., Alfonso V., Montaner J.S., et al. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. Antiviral Therapy 8 5 (2003) 471-478
8. Fitzmaurice G., Laird N., and Ware J. Applied longitudinal analysis (2004), John Wiley & Sons, Hoboken, NJ
9. Frankish C.J., Hwang S.W., and Quantz D. Homelessness and health in Canada: research lessons and priorities. Canadian Journal of Public Health 96 Suppl. 2 (2005) S23-S29
10. Gallant J.E., DeJesus E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine 354 3 (2006) 251-260
11. Health Canada. Reducing the harm associated with injection drug use in Canada. Report prepared by the Federal/Provincial/Territorial Advisory Committees on Population Health, Alcohol and Other Drug Issues, AIDS, and the Federal/Provincial/Territorial Heads of Corrections Working Group on HIV/AIDS (2001). Accessed 05.12.07
12. Health Canada, The Office of Alcohol, Drugs, and Dependency Issues. Canada's drug strategy (1998), Health Canada, Ottawa. Accessed 05.12.07
13. Heath K.V., Bally G., Yip B., O'Shaughnessy M.V., and Hogg R.S. HIV/AIDS care giving physicians: their experience and practice patterns. International Journal of STD & AIDS 8 9 (1997) 570-575
14. Hogg R.S., Bangsberg D.R., Lima V.D., Alexander C., Bonner S., Yip B., et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Medicine 3 9 (2006) 1570-1578
15. Hogg R.S., Heath K.V., Yip B., Craib K.J., O'Shaughnessy M.V., Schechter M.T., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279 6 (1998) 450-454
16. Hogg R.S., Schechter M.T., Schilder A., Le R., Strathdee S.A., Goldstone I.L., et al. Access to health care and geographic mobility of HIV/AIDS patients. AIDS Patient Care 9 6 (1995) 297-302
17. Hogg R.S., Whitehead J., Ricketts M., Heath K.V., Ng E., Lalonde P., et al. Patterns of geographic mobility of persons with AIDS in Canada from time of AIDS index diagnosis to death. Clinical and Investigative Medicine 20 2 (1997) 77-83
18. Joy R., Druyts E.F., Brandson E.K., Lima V.D., Rustad C.A., Zhang W., et al. Impact of neighborhood-level socioeconomic status on HIV-disease progression in a universal healthcare setting. Journal of Acquired Immune Deficiency Syndromes 47 4 (2008) 500-505
19. Laine C., Hauck W.W., and Turner B.J. Outpatient pattern of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Medical Care 40 10 (2002) 976-995
20. Last J.M. A dictionary of epidemiology. 4th ed. (2001), Oxford University Press, New York
21. Lima, V. D., Hogg, R. S., Gross, R., Bangsberg, D., Yip, B., Wood, E., et al. (2007). Marginal structural models for estimating the impact of longitudinal adherence on survival. In 11th International workshop on HIV observational databases, 22-25 March 2007, Monte Carlo, Monaco.
22. Lima V.D., Hogg R.S., Harrigan P.R., Moore D., Yip B., Wood E., et al. Continued improvement in survival among HIV infected individuals following initiation of triple and boosted combination antiretroviral regimens. AIDS 21 6 (2007) 685-692
23. Lima V.D., Johnston K., Hogg R.S., Levy A.R., Harrigan P.R., and Montaner J.S.G. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. Journal of Infectious Diseases 198 1 (2008) 59-67
24. Lucas G.M. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. Journal of Antimicrobial Chemotherapy 55 4 (2005) 413-416
25. Miller C.L., Spittal P.M., Wood E., Chan K., Schechter M.T., Montaner J.S., et al. Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations. AIDS Care 18 8 (2006) 968-976
26. Montaner J.S., Hogg R., Wood E., Kerr T., Tyndall M., Levy A.R., et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368 9534 (2006) 531-536
27. Moore R.D., and Chaisson R.E. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13 14 (1999) 1933-1942
28. Open Society Institute. Breaking down barriers: Lessons on providing HIV treatment to injection drug users (2004), Open Society Institute, New York
29. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338 13 (1998) 853-860
30. Pinheiro J.C., and Bates D.M. Mixed-effects models in S and S-PLUS. Statistics and Computing (2000), Springer-Verlag, New York
31. Rachlis B., Brouwer K.C., Mills E.J., Hayes M., Kerr T., and Hogg R.S. Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug and Alcohol Dependence 90 2-3 (2007) 107-119
32. Shryock H., and Siegel J. The Methods and Materials of Demography (1980), U.S. Department of Commerce, Bureau of Census, Washington
33. Tesoriero J., French T., Weiss L., Waters M., Finkelstein R., and Agins B. Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. Journal of Acquired Immune Deficiency Syndromes 33 4 (2003) 484-493
34. Van Leth F., Conway B., Laplumé H., Martin D., Fisher M., Jelaska A., et al., 2NN study group. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antiviral Therapy 9 5 (2004) 721-728
35. Wood E., Hogg R.S., Yip B., Harrigan P.R., O'Shaughnessy M.V., and Montaner J.S. The impact of adherence on CD4 cell count responses among HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 35 3 (2004) 261-268
36. Wood E., Montaner J.S., Bangsberg D.R., Tyndall M.W., Strathdeed S.A., O'Shaughnessy M.V., et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS 17 17 (2003) 2419-2427